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Abstract
This review explores similarities between lymphocytes and cancer cells, and proposes a new model
for the genesis of human cancer. We suggest that the development of cancer requires infection(s)
during which antigenic determinants from pathogens mimicking self-antigens are co-presented to
the immune system, leading to breaking T cell tolerance. Some level of autoimmunity is normal and
necessary for effective pathogen eradication. However, autoreactive T cells must be eliminated by
apoptosis when the immune response is terminated. Apoptosis can be deficient in the event of a
weakened immune system, the causes of which are multifactorial. Some autoreactive T cells suffer
genomic damage in this process, but manage to survive. The resulting cancer stem cell still retains
some functions of an inflammatory T cell, so it seeks out sites of inflammation inside the body. Due
to its defective constitutive production of inflammatory cytokines and other growth factors, a
stroma is built at the site of inflammation similar to the temporary stroma built during wound
healing. The cancer cells grow inside this stroma, forming a tumor that provides their vascular
supply and protects them from cellular immune response.
As cancer stem cells have plasticity comparable to normal stem cells, interactions with surrounding
normal tissues cause them to give rise to all the various types of cancers, resembling differentiated
tissue types. Metastases form at an advanced stage of the disease, with the proliferation of sites of
inflammation inside the body following a similar mechanism. Immunosuppressive cancer therapies
inadvertently re-invigorate pathogenic microorganisms and parasitic infections common to cancer,
leading to a vicious circle of infection, autoimmunity and malignancy that ultimately dooms cancer
patients. Based on this new understanding, we recommend a systemic approach to the
development of cancer therapies that supports rather than antagonizes the immune system.
Introduction
Understanding the pathomechanism of cancer is of pri-
mary interest in medical research. In the past century, sev-
eral mechanisms were proposed: It was hypothesized that
cancer arises out from a single cell that loses its differenti-
ated state through sequential mutations [1]. This initia-
tion-promotion-progression concept explains the steps in
a sequential process [2]. Later, this hypothesis led to the
mutagenic and recently the oncogenic theories which
hypothesize that defects in tumor suppressor genes are
responsible for the development of cancer [3]. The
impairment of cell-to-cell communication as a cause of
cancer has also been postulated [4].
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Mutations and other genetic abnormalities observed in
cancer cells could also be caused by environmental effects,
e.g., chemical carcinogens or life style factors such as alco-
hol or tobacco consumption or drug abuse [5]. The dis-
covery of the cancer stem cell [6-8] lent support to the
theory that cancer may develop out of a single cell, and
raised the question of cancer stem cells arising from nor-
mal stem cells [9]. Indeed, if normal stem cells could
undergo the type of mutations observed in tumor cells,
this would potentially compromise the genetic stability of
the organism. Therefore, the likelihood that normal stem
cells are extremely well protected is demonstrated by their
resistance to radiation and toxins [9].
One fascinating finding is that immunosuppressive cyto-
toxic antineoplastic therapies may on occasion cause the
regression of a clinically established cancer. At first, apply-
ing this as a therapeutic strategy may seem counterintui-
tive, considering the fundamental role of the immune
system in protecting the body against infectious organ-
isms and aberrant cells. In addition, cancer itself is fre-
quently immunosuppressive, so exacerbating a pre-
existing immunosuppression may not seem like a rational
strategy.
In this light, it appears paradoxical that the same degree of
immunosuppression that is lethal in a bacterial or fungal
infection actually benefits cancer suppression. In other
words, the deletion of the T cell compartment that accom-
panies cytotoxic antineoplastic therapies [10] may facili-
tate cancer regression. This suggests that cancer itself may
arise out of the immune system, potentially from the T cell
compartment, which would explain why the suppression
of cellular immunity could also lead to the suppression of
the disease.
Another observation is that tumor cells are poorly immu-
nogenic, despite the fact that tumor cells are antigenic
[11,12]. Therefore, they do not generate a T cell-mediated
immune response, and if so, it is of low intensity [13]. If
tumor cells were derived from injured lymphocytes, par-
ticularly T cells that still share some functional properties
with their normal counterparts, an immune tolerance to
cancer cells could be explained, as the immune system is
not made to attack itself. In pathological situations, T cells
do attack self-tissue in a manner reminiscent of the auto-
reactive nature of cancer cells which have the ability to
attack and invade host tissues. In other words, cancer cells
behave like autoreactive lymphocytes. Here, we explore
the evidence suggesting that such a mechanism could be
at work during the development of cancer.
The prevalent genetic theories of cancer are built upon
observations of genetic abnormalities in tumor cells.
These theories do not generally take into account the dem-
onstrated importance of environmental factors in human
cancer development. In a previous paper [14] we have
shown that specific dietary deficiencies mimic the effects
of chemical or radiation damage to DNA, which we pro-
pose plays an important role in human carcinogenesis
and tumorigenesis. This observation allows us to consider
cancer as a single disease, possibly developing from a sin-
gle cancer stem cell. Based on this, we could assume that
the observed genomic abnormalities in cancer cells are an
effect rather than the cause of the disease. This idea also
points to the direction of upstream events preceding the
development of the malignant cell. We propose that iden-
tifying these events will be fundamental to understanding
the pathomechanism of cancer. By exploring the func-
tional similarities between lymphocytes and cancer cells,
we provide an insight into this realm of possible upstream
events.
The exterior cell surface layer (cell coat)
The lymphocyte cell coat is a labile structure, and the
treatment of cells may lead to the loss of its components
[15-20]. The cell coat plays an important role in lym-
phocyte functions including homing, cell mediated
immunity, electrophoretic properties and antigen expres-
sion [21]; cell surface proteins are thought to be involved
in cell propagation and differentiation [18]. After treat-
ment with β-glucosidase [22], sialidase [23,24] and
trypsin [25], lymphocytes lose their homing abilities.
Cytotoxic lymphocytes transiently lose their cytotoxic
ability after a brief papain treatment [26]. Lysis of the cell
coat suppresses cell-mediated immunity [27-29]. Treat-
ment by glycosidases including neuraminidase affects the
bodily distribution of lymphocytes [23,24] and demon-
strates alterations in their antigenicity [30-34]. Treatment
with trypsin and neuraminidase reversibly eliminates the
mitogenic response of lymphocytes [35,36]. The cell coat
on thymocytes is significantly thicker than on splenic lym-
phocytes, [20] suggesting a role for the cell coat in T cell
function. The cell coat of the lymphocyte cell membrane
has been characterized using various stains [15-17], [37-
39]. These investigations found high acid mucopolysac-
charide content with a significant number of acidic amino
sugar end groups.
Cancer cells also exhibit an exterior cell surface coat [40-
45]. The similarities between the cell coat of normal and
leukemic lymphocytes have been investigated [39,41].
Pathological lymphocytes (CLL) have a uniformity of
staining similar to their normal counterparts, with some
differences observed with cationic stains that could be due
to a decrease in the sialoprotein of the cell coat of CLL
cells. With some similarity to lymphocytes, the tumor cell
coat has been suggested to play a role in cell contact and
adhesion, cell recognition [44], as well as the capacity to
metastasize [46].Molecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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The tumor cell coat is also sensitive to neuraminidase [47-
49] and can rapidly re-grow following treatment with the
enzyme [50]. The enzyme treatment also changes the
immunological properties of tumor cells. Trypsin and
EDTA removes the tumor cell coat [51]. The cell coat is
involved in the mechanism by which tumor cells escape
cellular immune attack [45,52-54]. The degradation of the
cell coat by brief hyaluronidase treatment of glioma cells
sensitizes them to cytotoxic lymphocyte attack [52,53].
Although normal human glial cells also produce
hyaluronic acid, glioma lines produced significantly
more. Hyaluronidase-sensitive coats have been found on
a variety of murine sarcoma and carcinoma cell lines [54].
It appears that a mucopolysaccharide coat on tumor cells
impedes the successful use of immunotherapy. It was
demonstrated that the displacement of the tumor cell coat
by charge-functionalized lipids or polycationic substances
leads to tumor cell apoptosis and tumor destruction
[45,55,56].
It is demonstrated that the cell coat of lymphocytes and
tumor cells are functionally significant. The degradation/
removal of cell coat significantly impacts the functionality
of both tumor cells and lymphocytes; therefore, tumor
cell isolation methods could alter the functionality of iso-
lated cells. In other words, with the loss of the cell coat,
lymphocytes lose fundamental functions, i.e., cannot
attack target cells, while tumor cells also lose cell contact
and adhesive properties, as well as the ability to metasta-
size. In addition, tumor cells become sensitive to apopto-
sis.
Activation of coagulation
The activation of coagulation occurs during tissue injury
as well as in various pathologies. Infection leads to an
inflammatory reaction as well as the activation of coagu-
lation, as there is a crosstalk between these functions [57-
59]. Blood coagulation components can inhibit or
amplify the inflammatory response. Blood clotting is ini-
tiated when pathogenic components such as endotoxin or
inflammatory cytokines induce the synthesis of tissue fac-
tor on leukocytes [60]. The coagulation cascade is subse-
quently triggered. The formation of negatively charged
membrane phospholipid surfaces amplifies the coagula-
tion reaction [61]. Natural anticoagulant pathways such
as the protein C anticoagulant pathway limit the coagula-
tion process, thereby suppressing the inflammatory
response including reducing inflammatory cytokine secre-
tion [62], decreasing NF-κB signaling [63], minimizing
leukocyte chemotaxis [64] and endothelial cell interac-
tions [65], and suppressing apoptosis [66].
Platelets are also involved in the link between inflamma-
tion and coagulation. Inflammatory cytokines such as IL-
6 or IL-8 increase platelet production, and such platelets
are more thrombogenic [67]. In addition, the platelets
release the CD40L protein, a potent proinflammatory
mediator, which subsequently induces tissue factor syn-
thesis [68,69] and amplifies the secretion of proinflam-
matory cytokines [70,71]. This in turn leads to a
progressive cycle that ultimately can produce severe vascu-
lar and organ injury.
In 1865, Trousseau first described a cancer-associated con-
dition now called migratory thrombophlebitis in which a
spontaneous coagulation of the blood occurs in the
absence of inflammatory reactions [72]. It manifests as
migratory thrombosis in the superficial veins of the chest
wall and arms, but it can occur in other sites as well. This
condition is a variant of venous thromboembolism.
Thrombosis is a frequent complication of malignancy,
and thromboembolic death is the second leading cause of
mortality in cancer [73,74]. Malignant cells interact with
the blood coagulation system by releasing procoagulant
and fibrinolytic substances and inflammatory cytokines
[75-85]. In addition, direct interaction with endothelial
cells, monocytes/macrophages, and platelets also leads to
localized clotting activation [85-87]. Similar to normal
activated inflammatory cells, malignant cells release tissue
factor [75-77] which promotes the formation of fibrin
deposits in the tumor cell microenvironment [88-90].
The fibrin gel matrix along with other connective tissue
components form the basis for the tumor stroma, a matrix
in which tumor cells are dispersed and which provides the
vascular supply as well as a barrier against rejection by the
cellular immune system [89]. The tumor stroma shares
properties in common with the temporary stroma of a
healing wound [91]. Similar to the fibrin coating on mac-
rophages [92], the observed fibrin coating of tumor cells
is involved in the mechanism by which tumor cells escape
destruction by NK cells [93,94]. Histological evidence sug-
gests that inflammatory lymphocytes are confined to the
tumor-host interface, and do no not significantly pene-
trate the tumor [89,95]. Malignant cells secrete inflamma-
tory cytokines such as TNF-α and IL-1β that downregulate
the anticoagulant system of vascular endothelial cells
[96,97]. The secretion of IL-8 promotes new blood vessel
formation, [98] and the fibrin deposited around tumor
cells facilitates angiogenesis [99-101].
Tumor cells attach to the vascular endothelium and pro-
mote the adhesion of leukocytes and platelets [102-105].
Monocytes and macrophages also home in on vascular
surfaces due to inflammatory stimuli [106-108]. In
response to inflammatory molecules, complement, lym-
phokines and immune complexes, these cells subse-
quently secrete procoagulant tissue factor; tumor-
associated macrophages express significantly higher levels
of tissue factor than control cells [109,110]. These macro-Molecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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phages also increase their fibrinolytic enzyme production
[111].
Both human and animal cancer causes platelet aggrega-
tion in vitro and in vivo [112-114]. The ability of tumor
cells to aggregate platelets and secrete plasminogen activa-
tor correlates with their metastatic potential [115].
Indeed, thrombocytopenia reduces the metastases of
tumors [116,117] as do compounds capable of reducing
platelet aggregation [117-125]. These include aspirin,
prostaglandins and other nonsteroidal (NSAID) anti-
inflammatory drugs. A reduced risk of fatal colon cancer
has been observed among aspirin users [120-122].
Administration of heparin and fibrinolysin also reduces
the incidence of experimental metastases [126-128],
while the administration of anti-fibrinolytic agents
increases their incidence [129,130].
Cancer treatment by surgery, cytotoxic antineoplastic
drugs and hormonal therapy all contribute to the hyper-
coagulable state and risk factors for thromboembolism in
cancer patients [131,132]. The risk of fatal pulmonary
embolism increases four-fold after surgery in cancer
patients [133,134]. Chemotherapy drugs including cyspl-
atin, mytomicin C and tamoxifen as well as high-dose and
multi-drug regimes increase the risk of thrombotic com-
plications [135-139]. Prophylactic treatment with warfa-
rin reduces this risk (140). The use of hematopoietic
growth factors subsequent to chemotherapy was shown to
induce thrombosis in breast cancer patients [141,142].
Venous thrombosis could also be a marker for an other-
wise asymptomatic cancer [143,144].
Similarly to a normal inflammatory reaction, activation of
coagulation takes place in cancer. The events of tumor
stroma development are comparable to wound healing
[91] and it is possible that tumor formation may be asso-
ciated with defective wound healing initiated by an
inflammatory reaction due to infection and/or tissue
injury. Therefore, we believe it is important to investigate
potential links between infection, inflammation and cel-
lular immune response in searching for the origins of the
cancer cell.
Infection and inflammation
The etiological role of infectious agents has been indi-
cated in various cancers. In 100 cases of human leukemia,
Mycoplasma,  Salmonella,  Micropolyspora,  Mycobacterium,
Absidia, pseudorabies virus and adenovirus antigens were
commonly detected in the patient's sera [145]. Hepato-
tropic viruses (hepatitis B and C) cause hepatic necrosis
followed by hepatocellular, B cell and gastric malignan-
cies [146-149]. Antiviral therapy of hepatitis C infection
led to the regression of virus-associated B cell lymphoma
[150]. Adenoviral infection has been associated with
childhood leukemia [151] and cytomegalovirus infection
with testicular cancer [152]. Helicobacter pylori infection is
widespread in the population (an estimated 40–80%
infected) and is linked to gastric cancer and mucosa-asso-
ciated lymphoid tissue (MALT) lymphoma [153,154]. A
reversal of lymphoma-induced neutropenia has been
observed with the eradication of H. pylori infection [154].
Simian virus 40 (SV40) is associated with human brain
cancers and non-Hodgkin's lymphoma [155]. Ocular
adnexal lymphoma is linked to Chlamydia psittaci infec-
tion, and the reversal of lymphoma was observed with
pathogen-eradicating antibiotic therapy [156]. The list
continues: Cervical intraepithelial neoplasia (CIN) is
associated with human papilloma virus (HPV) infection
with a co-etiological presence of chronic bacterial cervici-
tis [157-159]. Mycoplasma and HPV association was found
to be dominating. The role of mycoplasma in the dyspla-
sia of the uterine cervix and development of CIN has also
been demonstrated [160].
Mycoplasmas are particularly interesting due to their
widespread presence in the human population. Although
many mycoplasmas are not directly pathogenic in
humans, they are associated with many diseases [161-
165]. Mycoplasmas have co-leukemogenic activity [166-
168] and are found to increase tumor cell invasiveness
[169]. In approximately half of the examined cases, myc-
oplasma DNA was present in ovarian and gastric carci-
noma specimens [170,171]. In gastric, lung, esophageal,
breast and colon cancers as well as glioma specimens,
Mycoplasma hyorhinis was detected in about 50% of the
cases [172]. Mycoplasmas are known to cause chromo-
somal changes [173]. Mixed Mycoplasma pneumoniae and
influenza virus infection induced lung cancer in an ani-
mal model [174]. The direct role of the AIDS-associated
Mycoplasma fermentans and Mycoplasma penetrans in onco-
genesis has been investigated [175]. These mycoplasma
strains induced gradual malignant transformations that
eventually became irreversible. Besides its direct onco-
genic potential, Mycoplasma fermentans was found to
exhibit a unique cytocidal effect on the undifferentiated
myelomonocytic lineage, but not on differentiated myelo-
monocytic cells [176]. The depletion of immature myelo-
monocytic cells likely contributes to the functional
immunodeficiency present in cancer patients.
In response to pathogens, the host mounts a protective
inflammatory response. Immune cells migrate to the area
of infection and produce inflammatory messengers called
cytokines. Initially, cells of the innate immune system
(macrophages, neutrophils, NK cells) become involved,
followed by the activation of cells of the adaptive immune
system. These include antigen-presenting cells (APCs), T
and B cells, which play an important role in propagating
the inflammatory response. T cell inflammation plays aMolecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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major role in antitumor immune responses. Key regula-
tors of T cell-mediated response are the T helper (Th) cells
that secrete the cytokines orchestrating this response. The
two subtypes Th1 and Th2 cells produce cytokines stimu-
lating cellular and humoral immune responses.
Intracellular pathogens (e.g., viruses, mycoplasmas) use
the Toll-like receptor (TLR) signaling mechanism to
escape host defenses [177]. Pathogen-associated molecu-
lar patterns on the surface of mycoplasmas engage TLRs 1,
2, and 6 on the surface of APCs that lead to a Th2-type
polarization of the immune response and the secretion of
IL-10, IL-4, IL-5 and IL-13 [178-180]. These cytokines are
antagonistic to Th1 type cytokines (TNF-α, IL-2, IFN-γ, IL-
6, IL-12); excessive production of either type of cytokine
upsets the homeostatic balance needed to maintain a
proper mix of cellular and humoral immune responses.
Utilizing this mechanism, mycoplasmas suppress cell-
mediated immunity, which allows them to persist and
predispose the host for colonization by other pathogens.
The observation that leukemia patients were colonized by
over half a dozen pathogens besides mycoplasmas [145]
suggests that suppression of the cellular immune system
provides a fertile ground for a variety of pathologies.
Besides regulating innate and adaptive immune
responses, cytokines are involved in cell growth and dif-
ferentiation. Normally, the secretion of cytokines is of
short radius and limited duration, typically regulating self
or adjacent cell functions. The activity of cytokines is
tightly regulated, and there is evidence that cytokines con-
tribute to inflammatory autoimmune diseases [181-184]
and malignancies. Similarly to activated T cells, various
tumor cells secrete immune response-polarizing cytokines
(IL-10, IL-6, IL-8, IL-13, TGF-β) serving as autocrine and/
or paracrine growth factors for the cancer [185-199]. The
progression of the disease and patient survival was corre-
lated with increasing levels of cytokine secretion [200].
This secretion is frequently constitutive, leading to ele-
vated serum levels of cytokines in malignancies including
melanoma, non-small cell lung carcinoma, renal cell car-
cinoma and bladder carcinoma [186-190,201]. In addi-
tion, tumor cells can induce IL-10 in the tumor
environment [191]. IL-10, the most potent Th2 polarizing
cytokine, suppresses the tumoricidal activity of macro-
phages [202], blocks presentation of tumor antigens to
professional APCs [203-205], and inhibits tumor-specific
cytotoxic T cells [206]. However, in cancers both cellular
and humoral immune response may be depressed, as in
the absence of IL-4 production IL-10 secretion alone can-
not induce a Th2-type response.
It appears that the immune response becomes distorted at
multiple levels during the development of cancer. First,
infectious agents may act in concert to subvert cellular
immunity, thereby upsetting the homeostatic balance of a
proper mix of cellular and humoral immune response.
This leads to an aberrant cytokine-signaling that results in
depressed apoptosis and excessive proliferation
[207,208]. Cytokines seem to be the key substance of
apoptosis of leukemic cells [207]. Abnormal inflamma-
tory cytokine secretion by tumor cells reinforces the exist-
ing imbalances and thus promotes disease progression.
Similarly to T cells, cancer cells use inflammatory
cytokines as autocrine and paracrine growth factors, sug-
gesting a functional relationship between cancer cells and
cells of the immune system.
Infection, autoimmunity and cancer
Several lines of evidence suggest a direct relationship
between infection, autoimmunity and cancer. Hepatitis B
and C viruses are involved in an autoimmune condition
that precedes the development of hepatocellular carci-
noma [209]. Data also demonstrate a higher prevalence of
B-cell non-Hodgkin's lymphoma in HCV-infected
patients with autoimmune manifestations [147-149]
including Sjorgren syndrome [210], cryoglobulinemia
[211,212] and systemic lupus erythematosus (SLE)
[213,214]. Adenovirus infection is associated with child-
hood leukemia, (151) and family studies in acute child-
hood leukemia have shown possible associations with
autoimmune disease [215]. Epstein-Barr virus [216] and
human T lymphotropic virus type 1 infection [217] is
associated with abnormal lymphoproliferation and
Hodgkin's lymphoma. Cytomegalovirus infection is
linked to autoimmunity [218] and testicular cancer [152].
H. pylori infection can lead to autoimmune neutropenia
and MALT-lymphoma [154] in addition to its well-estab-
lished role in the development of gastric cancer. Systemic
rheumatic disease has also been linked to lymphoid
malignancy [219]. These findings underline a close rela-
tionship between infection, autoimmunity and prolifera-
tive disorders, possibly mediated by an abnormally
functioning cytokine signaling network [220].
Antinuclear antibodies (ANA) were demonstrated in the
sera of 19% of patients with malignancies in the absence
of overt autoimmune manifestations [221]. In cancer
patients, a large number of autoantibodies are observed
against tissue-specific antigens, nucleoproteins, mem-
brane receptors, proliferation-associated antigens, tissue-
restricted antigens, etc. [reviewed in [222]]. Autoimmune
connective tissue disorders are also commonly associated
with malignancies [223]. It was reported that gastric atro-
phy and pernicious anemia carries a risk for gastric carci-
noma 18 times that of the population average [224]. It
appears that a variety of infections may induce autoim-
mune serological features without overt autoimmune dis-
ease or organ involvement [225]; however, this conditionMolecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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may progress to clinical autoimmune disease and malig-
nancy if impaired T cell function prevails. Such condition
develops at a higher frequency among the elderly [226].
It was observed 30 years ago that a low percentage of
human T cells (3.4%) have the ability to form auto-
rosettes with autologous erythrocytes; in breast cancer and
melanoma patients, the ratio was elevated to 6.1% and
7.4%, respectively [227]. This observation implied that
some level of autoreactivity is normal, confirmed later by
studies on T cell tolerance [228,229]. However, the obser-
vation also pointed to an elevated level of autoreactive T
cells involved in cancer. The mechanism of activation of
an autoreactive T cell response was linked subsequently to
bacterial and viral infections through the process of
molecular mimicry [218,230-234] in which pathogen-
derived peptides mimic self-peptides. This phenomenon
was studied in animal models [235-240] and was sup-
ported by clinical observations [241-243]. As a highlight,
when lymphocytic choriomeningitis virus (LCV) antigens
were expressed in the pancreas of transgenic mice, infec-
tion with the virus led to autoimmunity and diabetes
[239].
H. pylori antigens mimic epitopes on H+, K+-adenosine tri-
phosphatase in the gastric mucosa [230] thereby activat-
ing cross-reactive gastric T cells. Viral peptides mimic
sequences on myelin basic protein [234], leading to mul-
tiple sclerosis. Cytochrome c (cyt c) as an antigen was used
to study how self-proteins prime autoreactive T cell
responses [244,245], as SLE patients possess autoantibod-
ies to cyt c [246]. When non-self cyt c was co-administered
with the self-protein, B cells specific for the foreign anti-
gen primed autoreactive T cells that led to breaking toler-
ance to self-cyt c. The same autoimmune phenomenon
occurs in the LCV transgenic mice when LCV antigens on
pancreatic cells and the intact virus antigens are co-pre-
sented to the immune system [239]. Therefore, it is quite
likely that autoimmunity spontaneously develops during
a variety of infections when antigens on microorganisms
mimic self antigens and are presented together, breaking
T cell tolerance.
The presence of autoreactive T cells has been observed in
healthy persons, which indicates a role for these cells in
immune defense. If autoreactive T cells were always
absent from the T cell repertoire, the responsiveness
toward foreign antigens that resemble self-antigens would
be reduced. This notion is supported by the observation
that T cells which recognized variants of self-antigen are of
lower avidity than those recognizing a foreign antigen
[247,248]. Also, tolerance to self-antigen reduced T cell
variants for these peptides as well as the diversity of T cell
receptor α and β-chain sequences of self-specific T cells
[249,250]. It appears that some level of autoreactive T
cells is necessary for immune defenses. Clinical autoim-
munity may develop when persistent infection provides a
continuing high dose of antigenic stimulus, [251] and this
situation could predispose patients for the development
of proliferative disorders.
Defective apoptosis
Normal tissue development requires damaged, dangerous
or unnecessary cells to be eliminated while healthy cells
survive. The survival of harmful or damaged cells can lead
to various pathologies. The evolutionarily conserved
mechanism of apoptosis eliminates unwanted or abnor-
mal cell populations. Lymphocytes require IL-2, IL-4, IL-
7, IL-9 and IL-15 for viability [252,253], and withdrawal
of these cytokines leads to apoptotic cell death. Leukemia
patients who went into complete remission following
chemotherapy developed a different type of leukemia
after being placed on IL-2 therapy [185]. IL-2 is an essen-
tial cytokine for the viability of activated T-cells [254],
suggesting a link between the survival of activated T-cells
and leukemic cells. Myeloid leukemia cells are also
cytokine-dependent and undergo apoptotic cell death fol-
lowing cytokine withdrawal [253]. The various immune
response-polarizing cytokines that tumor cells secrete
[185-201] inhibit chemotherapy- or radiation-induced
apoptosis [256-261]. There are myeloid leukemia cell
lines that have become independent of an external
cytokine supply [257], but generally cytokines can protect
both normal and cancer cells against apoptosis induced
by various cytotoxic agents. The persistence of infectious
agents and chronic inflammation in cancer patients pro-
motes NF-κB activation and inflammatory cytokine pro-
duction, thereby contributing to the diminished
apoptosis of abnormal cells [262,263].
The completion of immune response against pathogenic
microorganisms requires the deletion of activated T and B
cells that participated in the immune defenses, particu-
larly self-reactive ones [264] (although a fraction of them
survive as memory cells). Apoptosis plays an important
role in the regulation of peripheral immunity through the
Fas/APO-1 cytotoxic pathway. Defective apoptosis can
lead to autoimmune disease [265,266] and cancer
[267,268]. As cancer cells are not immortal, they maintain
a program for apoptotic cell death [269].
The apoptosis marker Fas receptor (FasR) is expressed on
numerous cell types, whereas the Fas ligand (FasL) is
mainly expressed on T cells [266]. FasL mediates the
apoptosis of effector T cells as part of an immune response
termination and tolerance development. FasL is also
expressed in "immune-privileged" tissues such as the
brain, testes and eyes with the purpose of preventing
inflammation. Mutations in Fas or FasL can lead to
autoimmune disease [270,271]. Similarly to cytotoxic TMolecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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cells, various tumor cells also express FasL and use it to
induce apoptosis of invading lymphocytes. Breast tumor
cells express FasL that can kill Fas-sensitive lymphoid cells
[272]. The co-expression of Fas and FasL was observed in
brain tumors that can use this mechanism to obtain a pro-
liferating advantage by "counter-attacking" tumor-infil-
trating activated Fas-sensitive T lymphocytes [273,274].
Similar observations have been made in Ewing sarcoma
[275], gastric cancer [276], cholangiocarcinoma [277], B
cell chronic lymphocytic leukemia (B-CLL) [278], colon
adenocarcinoma [279-281], head and neck cancer [282],
lung carcinoma [283], esophageal carcinoma [284], ovar-
ian carcinoma [285], lymphoma [286], pancreatic carci-
noma [287], melanoma [288], and other malignancies
[289,290]. Childhood glial tumor cells (but not normal
cells) in the brain express the common leukocyte-associ-
ated antigen and Fas [273].
The expression of apoptosis-related molecules on the sur-
face of both neoplastic cells and cytotoxic lymphocytes
(CTL) in tumor specimens raises the question of whether
neoplastic cells are formed from CTLs by a premature ter-
mination of the apoptotic mechanism. Indeed, neoplastic
cells behave like CTLs in their expression of FasL and in
the induction of apoptotic death of activated T cells, as
well as other cancer cells carrying a functional FasR
[291,292]. In other words, cancer cells continue to act like
T cells performing their immune-regulating functions.
Discussion and therapeutic implications
Infections by various pathogenic microorganisms are a
common occurrence in humans and other animals. In
response to invading pathogen(s), an inflammatory reac-
tion develops in the host organism. Initially, the innate
immune system becomes involved, followed by the devel-
opment of an adaptive immune response. Activated leu-
kocytes produce inflammatory cytokines and chemokines
as well as other growth factors aimed at clearing up the
infection and facilitating tissue healing. The inflammatory
reaction at the infection site triggers a variety of physiolog-
ical responses. Antigen-presenting cells activate T and B
cells in response to molecular patterns expressed on the
surfaces of pathogenic microorganisms. Intracellular
pathogens are overcome by the cellular immune response;
in addition, the T cell inflammatory reaction is also key to
antitumor immunity. Activated T helper 1 (Th1) cells
secrete specific cytokines orchestrating this response.
Pathogenic microorganisms, however, have evolved strat-
egies to evade immune surveillance in order to persist in
the host. Several intracellular pathogens including myco-
plasmas and viruses deploy molecular patterns on their
surfaces that trigger a Th2-type (humoral) immune
response and consequently depress cellular immunity. In
addition, some infections such as the mycoplasmas
remain sub-clinical, and by subverting the cellular
immune response, these microorganisms predispose the
host for colonization by other pathogens eventually lead-
ing to various pathologies.
Molecular mimicry is initiated when viruses integrate host
genes within their genome, [293] and pathogens with
host-like genes may have a survival advantage over those
lacking such traits. Animal viruses are capable of fusing
with prokaryotic cells that may facilitate gene transfer
between distant microbial taxa [294]. Influenza virus
hemagglutinin A sequences have been located in the p37
protein of Mycoplasma hyorhinis, and this protein increases
tumor cell invasiveness [295]. The exchange of genes
among various microorganisms [296] leads to the devel-
opment of antibiotic resistance. Gene uptake also occurs
by phagocytosis of apoptotic bodies [297,298] while High
Mobility Group (HMG) proteins, commonly associated
with human DNA, may facilitate this process in bacteria
[299].
When antigens from pathogens mimic self-antigens in the
process of molecular mimicry, cross-reactive T cells may
be generated. The study on breaking T cell tolerance with
co-administered foreign and self-cytochrome c is a sober-
ing reminder of just how easy is to induce autoimmunity.
However, evidence also demonstrates that a low level of
autoimmunity is normal and necessary to mount an effec-
tive immune response to infections. Clinical autoimmu-
nity may develop if a continuing high-dose antigenic
stimulus persists, as in cases of chronic infection. In addi-
tion, there is also evidence that autoimmunity can lead to
proliferative disorders.
As discussed, normal tissue development requires the
elimination of dangerous and abnormal cells, and
autoimmune T cells belong into this category. With the
completion of the immune response, the evolutionarily
conserved mechanism of apoptosis eliminates effector T
cells, leading to immune response termination and toler-
ance development. However, defective apoptosis can lead
to autoimmunity and cancer.
We propose that an aberration in the apoptosis process
leads to formation of the cancer stem cell from autoreac-
tive T cells. In support of this observation, Helicobacter-
induced gastric epithelial carcinoma was found to origi-
nate from bone marrow-derived cells [300]. This is direct
proof of cancer that is not arising from mutated epithelial
cells. Also, the cytotoxic T lymphocyte-associated antigen-
4 (CTLA-4), a regulator of the effector function of T cells,
is expressed in various leukemias and solid tumors [304].
This suggests a link between CTLs, hematopoietic neopla-
sias and solid tumors.Molecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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Further evidence: the common acute lymphoblastic leuke-
mia antigen was detected on glioma [301] and melanoma
[302] cell lines. The melanoma-associated PRAME anti-
gen is expressed both in leukemias and some solid tumors
[303]. The majority of leukemia and lymphoma cells test
positive for the leukocyte common antigen (CD45) [305].
Seminoma [306], rhabdomyosarcoma [307] and some
metastatic undifferentiated and neuroendocrine carcino-
mas [308] have also been found to express CD45. The
myeloid antigen Leu-7, typically expressed on natural
killer (NK) cells and T cell subsets, was detected on small
cell lung carcinoma [309,310] and a variety of other solid
tumors including astrocytoma, neuroblastoma, retino-
blastoma, carcinoid tumors, etc. [311]. Neoplastic cells of
Hodgkin's disease expressing Leu-7 may be related to NK
cells or T cells rather than B cells [312]. We propose that
the unexpected presence of some T cell markers on cancer
cells may provide an insight into their origins. In addition,
the observation that cancer stem cells embedded in an
environment of normal host tissue can undergo a differ-
entiation process (during which surface markers of lym-
phoid origin disappear) explains the absence of
leukocyte-derived surface antigens in some solid tumors.
In benign colonic adenomatous polyps and synchronous
adenocarcinoma, comparable and very large numbers of
genomic alterations (>10,000 events per cell) were found
[313], demonstrating massive genomic damage character-
istic of apoptosis as opposed to sequential mutations. In
addition, this demonstrates that genomic instability pre-
cedes the development of a malignant state, indicating
that malignancy is an effect rather than the cause of
genetic abnormalities in cancer cells. It is therefore reason-
able to conclude that there is no fundamental difference
between benign and malignant tumors, and that possibly
just a small difference in the disregulation of proliferative
controls leads to a malignant phenotype.
We further propose that the resultant cancer stem cell still
preserves some functions of an effector T cell, such as
homing in to sites of inflammation such as the inflamed
bronchi of a cigarette smoker, the damaged liver of an
alcohol abuser, an H. pylori-infected gastric mucosa, an
HPV-infected uterine cervix, an inflamed colon, etc. The
cancer cell retains some capabilities of an effector T cell to
secrete inflammatory cytokines (even if in an aberrant,
constitutive fashion), thereby distorting local immune
responses, disabling cytotoxic T cells and diminishing
apoptosis in its environment.
Like normal activated inflammatory cells, cancer cells acti-
vate the coagulation system, leading to the formation of
the tumor stroma in which tumor cells proliferate. Dvorak
in his paper entitled "Tumors: wounds that do not heal"
[91] succinctly described similarities between the forma-
tion of the temporary stroma of a healing wound and
tumor stroma development. While the cancer cell contin-
ues to act as if it participated in a wound healing process,
it actually enlarges the wound stroma due to its constitu-
tive secretion of tissue factor, inflammatory cytokines and
other growth factors which also provide stimuli for the
propagation of the malignant cells. This leads to an ever-
continuing cycle of tumor growth.
Every human cell has the ability to repair itself, and cancer
cells retain some of this capacity [314]. As cancer stem
cells exhibit plasticity similar to normal stem cells, we
propose that a cell-to-cell communication between cancer
stem cells and surrounding host tissues allows tumor cells
to develop varying degrees of differentiated phenotypes
resembling cells of normal differentiated tissues. This in
turn leads to the emergence of various tumor types and
creates the illusion of a great multitudes of cancers.
It has been long known that cancer cells, besides growing
inside tumors, also circulate in the blood [315-317]. This
is easy to rationalize if cancer cells are indeed damaged
autoreactive T cells, and also provides an explanation for
metastasis formation. Cancer cells interact with neu-
trophils, macrophages and platelets that lead to the for-
mation of micrometastases that can remain in the blood
for a long time [318]. These aggregates persist even after
adjuvant chemotherapy, although in reduced numbers.
Larger cell clumps are more effective in promoting metas-
tases than smaller ones [319]. With the progression of
inflammation in cancer patients, the circulating microme-
tastases find new sites of proliferation that lead to the for-
mation of metastases.
Current cancer therapies are tumor-centric, as tumors are
equated with cancerous disease. Main therapeutic modal-
ities include the surgical removal of tumors as well as radi-
ation and chemotherapies. All of these contribute to the
hypercoagulable state and risk of thromboembolism,
which have a significant negative impact on the morbidity
and mortality of cancer patients. If tumor cells did origi-
nate from T cells, any therapeutic approach targeting
tumor cells will likely diminish T cell function. Cytotoxic
antineoplastic therapy represents an extreme situation in
this regard, resulting in the deletion of even resting T cells,
the reconstitution of which takes several months [10].
This makes the combination of chemotherapy and immu-
notherapy an unrealistic proposition.
If cancer cells indeed originate from damaged autoreactive
T cells, our current views on cancer immunotherapy need
to be revised. The immune system was not made to attack
itself, and this is supported by the unresponsiveness of the
cellular immune system to cancer even if tumor cells are
antigenic. When we attempt to induce an immuneMolecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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response against tumors, we run the risk of developing
autoimmune disease [320] and ultimately, secondary
malignancies.
The suppression of the immune system by chemothera-
peutic agents and radiation encourages the propagation of
microbial and parasitic infections already present in can-
cer patients. However, pathogenic microorganisms are
intimately involved as co-etiological agents in the devel-
opment of various malignancies via molecular mimicry-
induced autoimmunity, and maintain a cytokine milieu
that favors proliferation as opposed to apoptosis. Current
immunosuppressive cancer therapies establish the condi-
tions for disease recurrence as well as the emergence of
new primary tumors, which is in fact, a common experi-
ence. Also, the cancer patient's system appears to retain a
"memory" of the disease as the risk of developing another
cancer is higher than those who have never had the dis-
ease. This memory could be attributed to autoimmune
memory T cells, reactivated by recurrent infections which
become cancerous later on as a consequence of defective
apoptosis.
The eradication of pathogens could have a favorable effect
on the course of malignant diseases, as demonstrated by
therapies of HCV [150], H. pylori [154], and Chlamydia
psittaci infections [156]. Mycoplasmas are difficult to erad-
icate and require high-dose, long-term antibiotic thera-
pies, but even after that the pathogens are found to persist
[321]. There are no therapies for many viral infections at
this time. With our new understanding of the mechanism
of TLR signaling, opportunities have opened for overcom-
ing these types of pathogens. Very recently, a therapeutic
oral mycoplasma vaccine was described [322], the princi-
ple of which could be utilized for the therapy of other
intracellular infections.
If defective apoptosis of autoreactive T cells leads to the
emergence of the cancer stem cell, our research must focus
on the physiological events associated with apoptosis.
Any therapeutic approach downstream from this step is
merely symptomatic, and offers little hope of defeating
cancer. A century of accumulated evidence on the use of
immunosuppressive cancer therapies supports this obser-
vation.
It was demonstrated that the exterior mucopolysaccharide
cell surface coat on cancer cells protects them from apop-
tosis [52,53]. Kovacs has explored this understanding to
the greatest degree by synthesizing unsaturated aminolip-
ids capable of displacing the cell coat on tumor cells [45].
Administration of these compounds led to the apoptotic
death of a variety of tumor cells in vitro and in vivo [45].
Normal lymphocytes are less sensitive to the apoptotic
effects of a fatty acid mixture than leukemic cells,
although they do show some sensitivity [323]. This obser-
vation may explain why the continuing administration of
synthetic unsaturated aminolipids led to a diminishing
efficacy of the therapy [324], as normal lymphocytes are
also surrounded by an exterior cell surface layer coat
essential for their functions.
Endocrine hormonal signaling also affects apoptosis. Cor-
ticosteroids facilitate the apoptosis of lymphocytes and
exert an immunosuppressive effect when the organism is
subject to prolonged stress. Stress also down-regulates the
digestive functions of the gut, including those of the stom-
ach and pancreas. This in turn suppresses the uptake of
critical nutrients that are essential for genomic stability
[14]. It was reported that breast cancer patients as a group
exhibit a depressed thyroid function [14], suggesting an
etiological role for thyroid deficiency in neoplasia. Thy-
roid function is profoundly affected by the iodine supply,
and thyroid, breast and gastric cancers have been linked to
iodine deficiency [14]. Previously we have pointed out
that critical nutrient deficiencies mimic the effects of
chemical or radiation damage to DNA, and suggested that
the correction of these deficiencies could reverse the pro-
gression of malignant proliferation [14].
In the past century, insufficient attention was paid to the
role of dietary factors in the development and progression
of malignant diseases. No Recommended Daily Allow-
ances (RDAs) are available for a number of essential nutri-
ents, and where available, the RDA is of questionable
value. Iodine, a vital micronutrient, is an example: the cur-
rent WHO recommendation for iodine is 0.15 mg/day.
However, some Japanese consume as much as 50–80 mg
of iodine/day through their seaweed rich diet [325] and
exhibit significantly lower rates of the major cancer types
than seen in the Western world [14]. In addition, iodine
supplementation clinical trials have demonstrated that an
iodine intake vastly exceeding the RDA (more than 6,000
times higher) was both safe and clinically useful
[326,327]. This could not possibly be the case if the RDA
for iodine had been correctly determined. Similar clinical
observations were made for high-dose administration of
folate and vitamin B12 [328,329] as well as vitamin C
[330]. These findings question the accuracy of dietary
RDAs, and suggest that current regulatory initiatives
aimed at restricting the active ingredient contents in vita-
min supplements are based on an erroneous scientific
rationale.
It is also important to recognize that vitamin and mineral
levels have significantly declined over the past 60 years in
our food supply [reviewed in [331]] possibly due to inten-
sive agricultural production methods and industrial food
processing. Experience teaches us that in the Western
world, despite an abundance of food, people have diffi-Molecular Cancer 2006, 5:6 http://www.molecular-cancer.com/content/5/1/6
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culties in meeting their nutritional needs, demonstrated
by now-rampant obesity as well as the historically proven
explosion of degenerative diseases including cardiovascu-
lar diseases, diabetes and cancer. This suggests that we are
still far from understanding the dietary needs of the
human organism.
It is known that diabetics develop malignancies at a
higher frequency than the population average [332,333],
which implicates pancreas dysfunction in the etiology of
cancer. Besides secreting digestive enzymes, the pancreas
is also a source of hormonal regulators. We hypothesize
that a combined effect of adrenal, thyroid and pancreas
dysfunction may predispose patients for neoplasia in a
process promoted by dietary deficiencies as well as life-
style factors including prolonged stress, poor hygiene,
smoking, alcoholism and drug abuse, all of which are
known to subvert immunity. It appears that we need to
make the most important scientific discoveries in the sim-
plest things, i.e., how to conduct our lives in a manner
optimal for well-being. Therefore, the main operative
principle of health care should be prevention.
To finally defeat cancer, our research need to focus on the
identification of those endocrine-signaling mechanisms
that enable CTLs to complete their mission of apoptotic
elimination of autoreactive T cells. We must abandon our
focus on the tumor cell as far as the development of cancer
therapeutics are concerned, as the destruction of cancer
itself negatively impacts the immune system, thereby reac-
tivating the vicious circle of infection, autoimmunity and
malignancy that ultimately dooms cancer patients. By
redirecting our focus toward physiological events preced-
ing the formation of the cancer stem cell, we will be able
to overcome this scourge that has haunted humanity since
time immemorial. A systemic approach described in a pre-
vious paper [14] offers an alternative to current cancer
therapies that works with the immune system, and which
helps to re-establish homeostatic balance in the human
body.
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